The global irritable bowel syndrome (IBS) treatment market is growing at a significant CAGR of around 9.5% during the forecast period (2020-2026). IBS is an intestinal disorder that causes abdominal pain, diarrhea, bloating, and constipation. According to the American Society of Gastrointestinal Endoscopy (ASGE), around 7-21% of the general population is suffering with IBS across the globe. There are few medications available in the market that offer relief to the disorder. In addition, there are several novel ongoing research activities associated with the IBS treatment through stem cell therapy. Stem cell therapy is one among those therapies that has been shown a significant relief in the condition of IBS. Therefore, the rise in stem cell research activities is expected to drive the IBS treatment market growth during the forecast period. 

Moreover, there are several factors that are driving the global IBS treatment market, which includes the increase in geriatric population coupled with the rising prevalence of IBS across the globe. The increasing aging population will grow the patient base with the malfunctioning of the digestive tract, which in turn, contributes in the market growth. According to the World Health Organization (WHO), the geriatric population is expected to get double by 2050, when compared to 2000. Globally, in 2000, the proportion of the people aged over 65 years were 11.0% of the global population, and these statistics are expected to reach 22.0% by 2050. In addition, the number of clinical trials and products under pipeline are expected to further drive the market growth during the forecast period. However, lack of awareness of IBS symptoms and treatment in underdeveloped economies will hamper the global market growth during the forecast period.

Segmental Outlook  

The IBS treatment market is classified on the basis of type and drug class. Based on type, the market is segmented into IBS-constipation, IBS-diarrhea, IBS-mixed, and IBS-unsubtyped. Based on drug class, the market is segregated into Eluxadoline, Linaclotide, Lubiprostone, and others. 

Global IBS treatment Market Share by Type, 2019 (%)

Source: OMR Global

Global IBS treatment market is driven by its rising prevalence of IBS-constipation

IBS-constipation is a majorly treatment IBS across the globe. in IBS-constipation, an individual feels a discomfort or bloating in the abdomen. It is the most diagnosed and treated IBS across the globe. There are several products under clinical trials that are associated with the treatment of IBS-constipation. This includes the products of Allergan PLC, Astellas Pharma, Inc., AstraZeneca PLC, and Ironwood Pharmaceuticals, Inc. Therefore, the IBS-constipation treatment market is estimated to project a considerable CAGR during the forecast period.

Regional Outlook 

The global IBS treatment market is classified on the basis of geography, which includes North America, Europe, Asia-Pacific, and Rest of the World. North America holds a significant share in the global IBS treatment market. The well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across the region will support the market growth over the forecast period. The US plays the critical role in geographic contribution of North America in global IBS treatment market, attributing to the significant diagnosis rate of IBS in the country. According to the American College of Gastroenterology, around 10-15% of the adult population in the US is suffering from IBS symptoms, though, nearly 5-7% of these adults have been diagnosed with the IBS. Moreover, IBS is one of the most common disease diagnosed by the US-based gastroenterologists, as per the same source. With such large diagnosis rate, the IBS treatment market holds a significant share in North America.

Global IBS treatment Market Growth, by Region 2020-2026

Europe is expected to propel with a considerable growth rate in the global market

Europe is estimated to project a considerable CAGR in the global IBS treatment market. Countries in Europe that are contributing to the market growth include UK, Germany, Spain, Italy, and France. Increasing population with IBS is expected to drive the diagnosis and treatment rate of IBS in Europe during the forecast period. Moreover, the presence of some of the key market players, such as Allergan PLC, AstraZeneca PLC, and GlaxoSmithKline PLC, is further estimated to propel the market growth in the region. The research on autoimmune diseases has gained momentum in UK and other European countries, which in turn, will drive the market growth in the region.

Market Players Outlook

The key players in the IBS treatment market are contributing significantly by providing advanced technology-based products and through expanding their geographical presence across the globe. The key players operating in the global IBS treatment market include Allergan PLC, Astellas Pharma, Inc., AstraZeneca PLC, Bausch Health Companies Inc., GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Co. Ltd. These market players adopt various strategies such as product launch, partnerships, collaborations, merger, and acquisitions to sustain a strong position in the market. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global IBS treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.